Reuters logo
BRIEF-Anaptysbio announces clearance of U.S., India, U.K. CTA for ANB020
December 13, 2016 / 1:17 PM / a year ago

BRIEF-Anaptysbio announces clearance of U.S., India, U.K. CTA for ANB020

Dec 13 (Reuters) - AnaptysBio Inc :

* AnaptysBio announces clearance of U.S. India and U.K. CTA for ANB020

* AnaptysBio - clearance for anb020regulatory support initiation of phase 2a trials for treatment of adult peanut allergy and atopic dermatitis

* AnaptysBio Inc - United Kingdom medicines and healthcare products regulatory agency has cleared company’s clinical trial authorisation for ANB020

* AnaptysBio- plans to initiate trials in Q1 of 2017, expects to complete trials during second half of 2017 in both U.S. And UK

* AnaptysBio Inc - during first half of 2017, seek regulatory clearance to initiate a phase 2a clinical trial for treatment of severe eosinophilic asthma Source text for Eikon: Further company coverage:

Our Standards:The Thomson Reuters Trust Principles.
0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below